About ZEO ScientifiX
ZEO ScientifiX is a publicly listed company based in Fort Lauderdale (United States) founded in 2011. Novel biological therapeutics are researched by the biopharmaceutical company. ZEO ScientifiX has raised $1 million across 2 funding rounds. Its chief executive, as recorded, is Harry Leider. ZEO ScientifiX offers products and services including PPX™, ZEO Hair Grow, and Aesthetics Biologics. Its focus areas include Life Sciences, Dermatology, Drugs and Aesthetics. Its competitors include Flexion Therapeutics, Formation Bio and MediciNova; 3 of its 3 listed competitors have raised funding.
Company details
ZEO ScientifiX was established in 2011 in Fort Lauderdale, United States, within the biopharmaceutical sector. Focus is placed on developing novel biological therapeutics. A concentrated autologous exosome product known as Patient Pure X is provided to reduce inflammation and support tissue healing through bioactive nanoparticles. Therapeutics featuring concentrated nanoparticles with microRNAs, lipids, enzymes, growth factors, and proteins are also supplied for regenerative and anti-aging applications in aesthetics.
- Headquarters Fort Lauderdale, United States
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website zeoscientifix.com
- Social LinkedIn X Facebook
- Legal Name Zeo Scientifix Inc.
- Annual Revenue$5.2 M (USD)12.53as on Oct 31, 2025
- Net Profit-$5.52 M (USD)-17.34as on Oct 31, 2025
- EBITDA-$5.31 M (USD)-1.3as on Oct 31, 2025
- Total Equity Funding$1M (USD)
in 2 rounds
- Latest Funding Round$500K (USD), Seed
Nov 2025
Products & Services of ZEO ScientifiX
ZEO ScientifiX offers a comprehensive portfolio of products and services, including PPX™, ZEO Hair Grow, and Aesthetics Biologics.
Concentrated autologous product for cell communication and tissue healing.
Exosome-based system to enhance hair health and growth.
Formulations for skin rejuvenation and inflammation reduction.
Funding Insights of ZEO ScientifiX
ZEO ScientifiX has successfully raised a total of $1M across 2 strategic funding rounds. The most recent funding activity was a Seed round of $500 thousand completed in November 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1M
- Total Rounds 2
- Last Round Seed — $500,000
- First Round $500,000
(Jul 2024)
All 2 funding rounds of ZEO ScientifiX with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2025 | $500,000 | Seed | – | – | – |
| Jul 2024 | $500,000 | Seed | – | – | – |
People of ZEO ScientifiX
56 people are tracked at ZEO ScientifiX (11 in leadership, 41 in board & advisors, 4 in team).
| Name | Role | Group |
|---|---|---|
Harry Leider | CEO | Leadership |
Howard L. Golub | EVP & Chief Science Officer | Leadership |
David Aciego | Chief Information Officer | Leadership |
Ian T. Bothwell | Chief Financial Officer | Leadership |
George Shapiro | Chief Medical Officer | Leadership |
Cassie Bennett | Director Of Quality And Compliance | Leadership |
Mark Sinnreich M.D. | Medical Director | Leadership |
Jacqueline D. | Vice President Operations | Leadership |
Jill Swartz | Chief Product Officer | Leadership |
Jackie Domenech | VP of Operations | Leadership |
Michael Bellio | Vice President Of Research And Manufacturing | Leadership |
Robert Madda | Medical Advisor | Board & advisors |
Paul Thompson | Medical Advisor | Board & advisors |
Julian Milberg | Science & Regulatory Advisor | Board & advisors |
Riley J. Williams III | Medical Advisor | Board & advisors |
Mark Zhuk | Medical Advisor | Board & advisors |
Allen J. Meglin | Medical Director, Board Member | Board & advisors |
Dennis J. Courtney | Medical Advisor | Board & advisors |
Paul Francis Campion | Medical Advisor | Board & advisors |
Rebecca Murray | Medical Advisor | Board & advisors |
36 more people are available in the full profile.
Complete people profiles for ZEO ScientifiX
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of ZEO ScientifiX
ZEO ScientifiX is a publicly listed company on the OTC with ticker symbol ZEOX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date08 Nov 2013
- Listed onOTC: ZEOX
- Listed entityZeo ScientifiX Inc.
- Exchange sectorHealth technology
- ISINUS68621D2062
- Share price$1.15 (-0.35% on the day) · 2026-10-13
- Market capitalisation$9.0M
- EPS (diluted, trailing year)$-0.59
- Volume (last session)6,720
Financials of ZEO ScientifiX
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $5.2M | -$5.5M | -$5.3M |
| 2024 | $4.6M | -$4.7M | -$5.2M |
| 2023 | $4.6M | -$7.0M | -$6.3M |
| 2022 | $6.5M | -$8.9M | -$8.5M |
| 2021 | $5.6M | -$12.8M | -$12.7M |
Detailed financial statements for ZEO ScientifiX
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of ZEO ScientifiX
4 dated milestones of ZEO ScientifiX across 14 years, from founding to its latest funding, stage changes and deals.
- Founded ZEO ScientifiX is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $500K.
- Funding Latest funding round, Seed, of $500K.
Competitors of ZEO ScientifiX
ZEO ScientifiX has 3 listed competitors in our database, 3 of them funded. They include Flexion Therapeutics, Formation Bio and MediciNova.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| flexiontherapeutics.com | 2007 | Woburn, United States | $62M | 692 | Developer of therapies for the treatment of musculoskeletal disorders | |
| formation.bio | 2016 | New York, United States | $608.25M | AI-powered drug discovery platform for various diseases | ||
| medicinova.com | 2000 | San Diego, United States | $83.94M | 13 | Small-molecule therapeutics are developed for asthma, COPD, and neurologic diseases. |
Detailed competitors of ZEO ScientifiX
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Orthopedics
3 companies that operate in the same segment as ZEO ScientifiX (Orthopedics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Provider of high-frequency spinal cord stimulation implants | 2006 | Menlo Park, California, United States | USD 154.1 M | USD 353.08 M | 1,215 | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
Antibody-siRNA complexes are developed for cancer treatment. | 2012 | San Diego, California, United States | USD 142.54 M | USD 10.9 M | 391 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Zeo Scientifix
Complete news archive for ZEO ScientifiX
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ZEO ScientifiX
ZEO ScientifiX was founded in 2011 and raised its 1st funding round 13 years after it was founded.
ZEO ScientifiX is headquartered in Fort Lauderdale, United States. It is registered at Fort Lauderdale, Florida, United States.
Harry Leider is the CEO of ZEO ScientifiX, as recorded in our data.
ZEO ScientifiX is a funded company, having raised a total of $1M across 2 funding rounds to date. The company's 1st funding round was a Seed of $500K, raised on Jul 2024.
Annual revenue of ZEO ScientifiX is $5.2M as on Oct 31, 2025.
ZEO ScientifiX was established in 2011 in Fort Lauderdale, United States, within the biopharmaceutical sector. Focus is placed on developing novel biological therapeutics. A concentrated autologous exosome product known as Patient Pure X is provided to reduce inflammation and support tissue healing through bioactive nanoparticles. Therapeutics featuring concentrated nanoparticles with microRNAs, lipids, enzymes, growth factors, and proteins are also supplied for regenerative and anti-aging applications in aesthetics.
ZEO ScientifiX's top competitors include Flexion Therapeutics, Formation Bio and MediciNova.
ZEO ScientifiX offers PPX™, ZEO Hair Grow, and Aesthetics Biologics.
Yes, ZEO ScientifiX is publicly traded on OTC under the ticker symbol ZEOX.
ZEO ScientifiX operates through Zeo Scientifix.